Ketamine

Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery

Retrieved on: 
Wednesday, February 14, 2024

SARASOTA, FL, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today provided a positive update on SP-26, its novel time-released, dose-controlled formulation of ketamine initially targeted for fibromyalgia. A pre-clinical research study is underway involving analytical testing services and small batch proof-of-concept extrusion trials to determine drug release and stability.

Key Points: 
  • A pre-clinical research study is underway involving analytical testing services and small batch proof-of-concept extrusion trials to determine drug release and stability.
  • In recent testing, SP-26 polymer implants were blended with ketamine hydrochloride (ketamine HCL) in two loadings, 20% and 40%.
  • “Implantable drug delivery systems like SP-26 may provide sustained drug delivery for prolonged periods of time, which is critical for the treatment of chronic pain conditions,” said Eric Weisblum, CEO of Silo.
  • Silo believes that implantable drug delivery systems (IDDS) can offer a superior delivery alternative for sustained relief from chronic pain.

Silver Hill Hospital Launches Outpatient Ketamine Treatment Program for Depression

Retrieved on: 
Wednesday, February 14, 2024

Silver Hill Hospital , one of the nation’s premier psychiatric hospitals, has opened its Ketamine Treatment Program , bringing a powerful therapeutic intervention to patients with treatment-resistant depression.

Key Points: 
  • Silver Hill Hospital , one of the nation’s premier psychiatric hospitals, has opened its Ketamine Treatment Program , bringing a powerful therapeutic intervention to patients with treatment-resistant depression.
  • With this opening, Silver Hill joins a select number of hospitals with comprehensive mental health services administering ketamine treatment.
  • In keeping with the environment of restorative care at Silver Hill, the Ketamine Treatment Program was deliberately designed to maximize comfort conducive to healing.
  • “With our research-backed protocol, expert medical staff, and the oversight of Dr. Prueitt, the Ketamine Treatment Program is poised to help patients who have not responded to more traditional depression treatment methods and may have been losing hope.”
    The Silver Hill Hospital Ketamine Treatment Program is available to outpatients, as well as inpatients and residential patients, and it is now accepting referrals.

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

Retrieved on: 
Monday, February 12, 2024

TORONTO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, provides an update of its Priority Original Abbreviated New Drug Application (“ANDA”) for Ketamine that was accepted by the U.S. Food and Drug Administration (the “FDA”) and assigned a Generic Drug User Fee Amendments of 2022 (“GDUFA”) goal date of April 29, 2024.

Key Points: 
  • TORONTO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, provides an update of its Priority Original Abbreviated New Drug Application (“ANDA”) for Ketamine that was accepted by the U.S. Food and Drug Administration (the “FDA”) and assigned a Generic Drug User Fee Amendments of 2022 (“GDUFA”) goal date of April 29, 2024.
  • The Company aims to respond to satisfy the preliminary thoughts on possible deficiencies before the goal date.
  • The Company received a waiver from the FDA for bioequivalence studies and has not identified any deficiencies.
  • A recently published new peer-reviewed study on the real-world effectiveness of ketamine intravenous therapy demonstrated significant patient improvement for depression, anxiety and suicidal ideation.

Relief Mental Health Expands Access to Treatment: IV Ketamine Now Available in Additional Chicagoland Clinics

Retrieved on: 
Tuesday, February 6, 2024

Relief Mental Health , a leading provider of innovative mental health treatments, announced today the expansion of IV ketamine to multiple clinics across the Chicagoland area, including Chicago West Loop, Northbrook, Oak Brook , Orland Park and St. Charles.

Key Points: 
  • Relief Mental Health , a leading provider of innovative mental health treatments, announced today the expansion of IV ketamine to multiple clinics across the Chicagoland area, including Chicago West Loop, Northbrook, Oak Brook , Orland Park and St. Charles.
  • "We are pleased to extend our IV ketamine services to additional clinics throughout Chicagoland," said Susan Mueller, CEO, Relief Mental Health.
  • The decision to expand IV ketamine treatment services reflects Relief’s commitment to providing comprehensive, personalized care to patients in need.
  • Relief Mental Health remains steadfast in its dedication to promoting mental wellness and empowering individuals to reclaim their lives from the grips of mental illness.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces the Incorporation of HOPE Therapeutics, Inc., and Planned Share Dividend/Royalty Coupon

Retrieved on: 
Monday, February 5, 2024

This is designed with counsel to not be a taxable event for shareholders.

Key Points: 
  • This is designed with counsel to not be a taxable event for shareholders.
  • "Incorporating HOPE Therapeutics is another important step in building value for NRx shareholders.
  • HOPE is dedicated to providing an FDA-approved presentation of IV Ketamine, manufactured to current federal standards, in a diversion- and abuse-deterrent presentation.
  • NRx also expects to convene a shareholder meeting in the coming weeks to vote on the planned structure of the spin-out of Hope Therapeutics and the stock dividend.

Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology

Retrieved on: 
Thursday, February 1, 2024

SARASOTA, FL, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced updates for its strategic 2024 focus for its clinical pipeline. The Company is advancing a diversified portfolio of four drugs targeting three health areas: mental health, chronic pain, and neurology.

Key Points: 
  • The Company is advancing a diversified portfolio of four drugs targeting three health areas: mental health, chronic pain, and neurology.
  • A dose-ranging non GLP study of SPC-15 is in progress, with a final validation report expected in the first half of 2024.
  • As a self-administered treatment, SP-26 holds the potential to be the first at-home ketamine treatment approved for chronic pain management.
  • Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases.

Relief Mental Health Honors Psychiatric Physician Assistant Jamie Pacilio as Provider of the Month

Retrieved on: 
Tuesday, January 30, 2024

Relief Mental Health is proud to announce Jamie Pacilio, MSPAS, PA-C , psychiatric physician assistant in its Red Bank clinic , as the recipient of its prestigious Provider of the Month award.

Key Points: 
  • Relief Mental Health is proud to announce Jamie Pacilio, MSPAS, PA-C , psychiatric physician assistant in its Red Bank clinic , as the recipient of its prestigious Provider of the Month award.
  • As a highly skilled psychiatric medical provider, Pacilio has been an integral part of Relief’s mission in New Jersey to deliver comprehensive and personalized mental health services.
  • One of the distinctive offerings at Relief Mental Health is transcranial magnetic stimulation (TMS) therapy, and Pacilio has played a key role in the success of this initiative.
  • Relief congratulates Pacilio on this well-deserved honor and expresses gratitude for her continued contributions to the field of mental health.

Complete Ketamine Solutions Launches Breakthrough Addiction Recovery Program

Retrieved on: 
Tuesday, January 30, 2024

STAMFORD, Conn., Jan. 30, 2024 /PRNewswire-PRWeb/ -- Complete Ketamine Solutions of Stamford (CKS), a pioneer in ketamine therapy, is proud to announce the launch of its groundbreaking Addiction Recovery Protocol, aimed at providing a comprehensive and effective solution for individuals battling addiction. This 6-week intensive program integrates cutting-edge ketamine infusions, NAD infusions, and specialized IV medications, combined with talk therapy, to address addiction challenges with a holistic approach.

Key Points: 
  • Transformative Addiction Treatment Integrates Ketamine and NAD Infusions at Stamford, CT Location
    STAMFORD, Conn., Jan. 30, 2024 /PRNewswire-PRWeb/ -- Complete Ketamine Solutions of Stamford (CKS), a pioneer in ketamine therapy , is proud to announce the launch of its groundbreaking Addiction Recovery Protocol , aimed at providing a comprehensive and effective solution for individuals battling addiction.
  • "We are witnessing profound transformations through our Addiction Recovery Protocol, reinforcing our belief in the power of ketamine therapy."
  • The Addiction Recovery Protocol consists of 8 two-hour ketamine infusions, 6 NAD infusions, and personalized IV medications administered during each session.
  • CKS recognizes the pressing need for innovative solutions in addiction recovery and aims to raise awareness about the efficacy of ketamine therapy in addressing not only mood disorders but also addiction.

PharmaTher Provides Update for Expected FDA Approval of Ketamine

Retrieved on: 
Wednesday, January 10, 2024

The assigned FDA approval goal date is still on track.

Key Points: 
  • The assigned FDA approval goal date is still on track.
  • Fabio Chianelli, CEO of PharmaTher, commented: “We believe 2024 will be a transformative year for PharmaTher with the expected FDA approval of ketamine having an assigned goal date for approval on April 29, 2024.
  • On October 10, 2023, the FDA published a compounding risk alert describing the potential risks associated with compounded ketamine products for psychiatric disorders, specifically from telehealth providers that provide in-home ketamine services.
  • Following the FDA approval and launch in the U.S., the Company will pursue international approvals to support the global demand for ketamine.

Melt Pharmaceuticals Provides Corporate Update

Retrieved on: 
Wednesday, January 3, 2024

Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today provided a corporate update.

Key Points: 
  • Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today provided a corporate update.
  • Melt Pharmaceuticals recently received a written response from the U.S. Food and Drug Administration (FDA) regarding its planned MELT-300 Phase 3 program.
  • Based on the FDA’s response, Melt Pharmaceuticals expects to begin Phase 3 program activities, which will consist of a single pivotal study comparing MELT-300 to sublingual midazolam and placebo in subjects undergoing cataract surgery, in the first quarter of 2024.
  • Following this transaction, in addition to certain royalty rights, Harrow’s equity ownership percentage of Melt is approximately 47%.